UCB (OTCMKTS:UCBJY) Upgraded at Jefferies Financial Group

UCB (OTCMKTS:UCBJY) was upgraded by investment analysts at Jefferies Financial Group to a “moderate sell” rating in a research note issued on Sunday,Zacks.com reports.

Other analysts have also issued reports about the stock. Zacks Research upgraded shares of UCB from a “hold” rating to a “strong-buy” rating in a report on Friday, August 29th. The Goldman Sachs Group upgraded shares of UCB to a “strong-buy” rating in a research report on Wednesday, July 16th. Two analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat, the company has a consensus rating of “Strong Buy”.

UCB Stock Performance

OTCMKTS:UCBJY opened at $139.90 on Friday. UCB has a 52 week low of $71.16 and a 52 week high of $151.76. The stock’s fifty day moving average is $130.10 and its two-hundred day moving average is $107.13.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.